Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70358 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Aleece MacPhail und 14 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine Nursing and Health Science, Monash University, Clayton, Victoria, Australia. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Febrile Neutropenia, Leukemia, Myeloid, Acute. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Febrile neutropenia causes substantial morbidity in acute myeloid leukaemia and higher risk myelodysplastic syndrome. We aimed to describe current practice and priorities for clinical trials in the prevention and management of febrile neutropenia across Australia/New Zealand (ANZ), the United Kingdom (UK), Canada and Europe. We performed an international survey of haematologists recruited via professional networks. Eighty‐five unique hospitals were represented (ANZ = 20; Canada = 14; UK = 30; Europe = 21). Antibacterial prophylaxis was more commonly prescribed in Canada (79%) and the UK (83%) than in ANZ (30%) and Europe (48%, p < 0.001), and was prescribed more frequently to outpatients than inpatients. The most common empiric treatment was piperacillin–tazobactam monotherapy (66/84, 79%), with nurse‐initiated antibiotic orders used in 35/84 (42%). Screening for multidrug‐resistant organisms varied and was not usually used to direct antibiotic treatment. Antibiotic de‐escalation was attempted in most institutions; for uncomplicated short‐lived fever of unknown source, 39/85 (46%) reported ceasing antibiotics at 72 h and 68/85 (80%) within 7 days. For patients with bacteraemia, de‐escalation strategies included narrowing spectrum, oral switch and cessation after defined duration. Most respondents (79/85, 93%) reported interest in recruiting for clinical trials. Clinical trials addressing practice variability in febrile neutropenia are needed, and are supported by haematologists.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine Nursing and Health Science, Monash University, Clayton, Victoria, Australia.
- Monah Infectious Diseases, Monash Health, Clayton, Victoria, Australia.
- Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- University of Birmingham, Birmingham, UK.
- CancerCare Manitoba, Winnipeg, Manitoba, Canada.
- Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
ORCID-Profile: Brett L Houston, Andrea S Henden, Robert Weinkove, Catriona Parker, Simon J Stanworth, Zoe McQuilten
Zitieren
APA
MacPhail, A., Loke, J., Houston, B. L., Dendle, C., Henden, A. S., Weinkove, R., Morrissey, O., Neofytos, D., Buetti, N., Parker, C., Slavin, M. A., Craddock, C., Stanworth, S. J., McQuilten, Z., & Australasian Leukaemia and Lymphoma Group Supportive Care Working Group and UK AML/Supportive Care Working Parties (2026). Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice. British Journal of Haematology. https://doi.org/10.1111/bjh.70358
Vancouver
MacPhail A, Loke J, Houston BL, Dendle C, Henden AS, Weinkove R, et al. Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice. British Journal of Haematology. 2026. doi:10.1111/bjh.70358
BibTeX
@article{MacPhail2026,
author = {MacPhail, Aleece and Loke, Justin and Houston, Brett L and Dendle, Claire and Henden, Andrea S and Weinkove, Robert and Morrissey, Orla and Neofytos, Dionysios and Buetti, Niccolò and Parker, Catriona and Slavin, Monica A and Craddock, Charles and Stanworth, Simon J and McQuilten, Zoe and Australasian Leukaemia and Lymphoma Group Supportive Care Working Group and UK AML/Supportive Care Working Parties, Australasian Leukaemia and Lymphoma Group Supportive Care Working Group and UK AML/Supportive Care Working Parties},
title = {Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70358}
}
EUVIMED